Conversely, in cancers where DCs are abundant in the TME, such as melanoma, Dectin-1 activation boosts cross-presentation of tumor antigens, leading to Th9 differentiation and a stronger anti-tumor response [17]. This evidence concerns the gene CLEC7A and melanoma.